PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats

  title={PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats},
  author={Amanda E. Higley and Krista J Spiller and Peter Grundt and Amy Hauck Newman and Stephen W. Kiefer and Zheng-Xiong Xi and Eliot L. Gardner},
  journal={Journal of Psychopharmacology},
  pages={263 - 273}
Our previous studies have shown that the selective dopamine D3 receptor antagonists SB-277011A or NGB 2904 significantly attenuate cocaine self-administration under a progressive-ratio reinforcement schedule and cocaine-, methamphetamine- or nicotine-enhanced brain stimulation reward. However, the poor bioavailability of SB-277011A has limited its potential use in humans. In the present study, we investigated the effects of the novel D3 receptor antagonist PG01037 on methamphetamine self… 

Figures from this paper

Role of dopamine D2-like receptors and their modulation by adenosine receptor stimulation in the reinstatement of methamphetamine seeking
These results demonstrate the sufficiency of dopamine D3 receptors to reinstate MA seeking that is inhibited when combined with adenosine A1 receptor stimulation.
A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice
Brain D3 receptors are critically involved in the reward and psychomotor-stimulating effects of METH, and YQA14 deserves further study as a potential medication for METH addiction.
Dopamine D1 and D3 Receptor Polypharmacology in Cocaine Reward and Cocaine Seeking
The aims of this dissertation were to evaluate the effects of the novel strategy of simultaneous treatments with a D3 receptor antagonist and D1 receptor partial agonist in animal models of drug addiction, including cue-induced reinstatement of cocaine seeking, cocaine conditioned place preference (CPP) and cocaine self-administration in rats.
Nucleus accumbens hyperpolarization-activated cyclic nucleotide-gated channels modulate methamphetamine self-administration in rats
Results indicate that HCN channels in the nucleus accumbens are involved in the reinforcing properties of methamphetamine and highlight the importance of HCNannels in the regulation of dopamine neurotransmission underlying methamphetamine addiction.


Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.
The data reviewed in this paper suggest that NGB 2904 or other D3-selective antagonists may have potential in controlling motivation for drug-taking behavior or relapse to drug-seeking behavior, but may have a limited role in antagonizing the acute rewarding effects produced by cocaine or other addictive drugs.
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.
The results suggest that selective D3 receptor antagonism constitutes a new and promising pharmacotherapeutic approach to the treatment of nicotine dependence.
Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats
An important role for D3 receptors in mediating the addictive properties of cocaine is suggested and blockade of dopamine D3receptors may constitute a new and useful target for prospective pharmacotherapies for cocaine addiction.
The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats
Findings support a potential use of selective D3 receptor antagonists for the treatment of METH addiction and suggest that the METH-enhanced BSR attenuation produced by BP-897 may involve both D3 and non-D3 receptors.
The Novel Dopamine D3 Receptor Antagonist NGB 2904 Inhibits Cocaine's Rewarding Effects and Cocaine-Induced Reinstatement of Drug-Seeking Behavior in Rats
The data show that the novel D3-selective antagonist NGB 2904 attenuates cocaine's rewarding effects as assessed by PR self-administration, BSR, and cocaine-triggered reinstatement of cocaine-seeking behavior.
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist
BP 897 inhibits cocaine-seeking behaviour that depends upon the presentation of drug-associated cues, without having any intrinsic, primary rewarding effects, which indicates that compounds like BP 897 could be used for reducing the drug craving and vulnerability to relapse that are elicited by drug- associated environmental stimuli.
The dopamine D3 receptor and drug addiction
BP 897 has the unprecedented property to reduce cocaine-seeking behavior induced by presentation of a cocaine-associated cue, without having any intrinsic reinforcing effect, and may represent new medications for drug addiction, with minimal liability to maintaining dependence.